TriSalus Life Sciences (TLSI) Liabilities and Shareholders Equity (2020 - 2026)

TriSalus Life Sciences' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $71.0 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 147.96% year-over-year to $71.0 million; the TTM figure through Mar 2026 stood at $184.1 million (up 63.63% YoY), while the FY2025 annual figure was $35.3 million, up 47.39% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $71.0 million, up from $35.3 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $251.3 million in Q3 2022, with the low at $12.2 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $32.4 million (2024), against an average of $69.4 million.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity tumbled 95.12% in 2023, then soared 165.01% in 2024.
• TriSalus Life Sciences' Liabilities and Shareholders Equity stood at $22.0 million in 2022, then grew by 11.83% to $24.6 million in 2023, then declined by 2.55% to $24.0 million in 2024, then surged by 47.39% to $35.3 million in 2025, then soared by 100.9% to $71.0 million in 2026.
• Business Quant data shows TLSI's Liabilities and Shareholders Equity at $71.0 million in Q1 2026, $35.3 million in Q4 2025, and $36.5 million in Q3 2025.